SC-VC-PAB-MMAE
Based on 2 publication(s) in Google Scholar
SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
For research use only. We do not sell to patients.
- Purity : 99.07%
- CAS No.: 2259318-46-0
- Formula: C68H105N11O17
- Molecular Weight:1348.62
-
Storage:
-20°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13631E
DeruxtecanDrug-Linker Conjugates for ADC -
HY-101070
SMCC-DM1Drug-Linker Conjugate for ADC -
HY-131056
Gly3-VC-PAB-MMAEDrug-Linker Conjugates for ADC -
HY-15575
VcMMAEDrug-Linker Conjugate for ADC -
HY-112786
MC-Val-Cit-PAB-MMAFDrug-Linker Conjugate for ADC -
HY-133492
DBCO-PEG4-MMAFDrug-Linker Conjugate for ADC -
HY-126682
Mal-VC-PAB-DM1Drug-Linker Conjugate for ADC -
HY-128955
MC-VC-PABC-Aur0101Drug-Linker Conjugates for ADC -
HY-136286
MC-DM1Drug-Linker Conjugate for ADC -
HY-126491
SPP-DM1Drug-Linker Conjugates for ADC -
HY-100567
MAL-di-EG-Val-Cit-PAB-MMAEDrug-Linker Conjugate for ADC -
HY-126494
DM4-SMCCDrug-Linker Conjugate for ADC
Publications Citing Use of MedChemExpress (MCE) SC-VC-PAB-MMAE
MoreAll Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Auristatin |
In Vitro
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2259318-46-0
-
Appearance Solid
-
Molecular Weight 1348.62
-
Formula C68H105N11O17
-
Color White to off-white
-
SMILES
O=C([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCC(ON1C(CCC1=O)=O)=O)=O)=O)NC(C=C2)=CC=C2COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N3[C@H]([C@H](OC)[C@@H](C)C(N[C@@H]([C@@H](O)C4=CC=CC=C4)C)=O)CCC3)=O)=O)=O)=O
-
Synonyms
NHS-VC-PAB-MMAE
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Pharm Sci
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads. [Abstract]2024 Aug;113(8):2443-2453. PMID: 38679234 -
J Pharm Sci
Agitation-Induced Aggregation of Lysine- and Interchain Cysteine-Linked Antibody-Drug Conjugates. [Abstract]2024 May;113(5):1265-1274. PMID: 38070776
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (74.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7415 mL | 3.7075 mL | 7.4150 mL | 18.5375 mL |
| 5 mM | 0.1483 mL | 0.7415 mL | 1.4830 mL | 3.7075 mL | |
| 10 mM | 0.0741 mL | 0.3707 mL | 0.7415 mL | 1.8537 mL | |
| 15 mM | 0.0494 mL | 0.2472 mL | 0.4943 mL | 1.2358 mL | |
| 20 mM | 0.0371 mL | 0.1854 mL | 0.3707 mL | 0.9269 mL | |
| 25 mM | 0.0297 mL | 0.1483 mL | 0.2966 mL | 0.7415 mL | |
| 30 mM | 0.0247 mL | 0.1236 mL | 0.2472 mL | 0.6179 mL | |
| 40 mM | 0.0185 mL | 0.0927 mL | 0.1854 mL | 0.4634 mL | |
| 50 mM | 0.0148 mL | 0.0741 mL | 0.1483 mL | 0.3707 mL | |
| 60 mM | 0.0124 mL | 0.0618 mL | 0.1236 mL | 0.3090 mL |
SC-VC-PAB-MMAE Related Classifications
HY-126681 Related Classifications
Powered by Bioz